MCID: LMN006
MIFTS: 37

Luminal Breast Carcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma

Aliases & Descriptions for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma 12 14
Luminal Breast Cancer 12
Breast Tumor Luminal 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as luminal breast cancer, is related to breast cancer and bartholin's gland benign neoplasm. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin), and among its related pathways/superpathways are Glioma and Development HGF signaling pathway. The drugs Estrogens and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are Decreased viability and growth/size/body region

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
id Related Disease Score Top Affiliating Genes
1 breast cancer 10.5
2 bartholin's gland benign neoplasm 10.3 ESR1 PGR
3 mouth disease 10.3 ERBB2 PGR
4 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
5 appendix leiomyoma 10.3 ESR1 PGR
6 bronchus adenoma 10.3 ESR1 PGR
7 ovarian benign neoplasm 10.3 ESR1 PGR
8 plexiform neurofibroma 10.3 ESR1 PGR
9 hereditary breast ovarian cancer 10.3 ERBB2 ESR1
10 pineal region mature teratoma 10.3 EGFR ERBB2
11 paranasal sinus disease 10.3 ESR1 PGR
12 deafness, autosomal recessive 21 10.3 ESR1 PGR
13 atypical lipomatous tumor 10.3 ESR1 PGR
14 severe pre-eclampsia 10.3 EGFR MTOR
15 pediatric intraocular retinoblastoma 10.3 ESR1 PGR
16 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
17 perlman syndrome 10.2 ESR1 PGR
18 polycythemia 10.2 MTOR PGR
19 bladder adenocarcinoma 10.2 ESR1 PGR
20 anal neuroendocrine tumor 10.2 ESR1 PGR
21 osteogenesis imperfecta 10.2 ESR1 PGR
22 glioma 10.2 ERBB2 ESR1 PGR
23 histiocytic and dendritic cell cancer 10.2 ERBB2 ESR1 PGR
24 her2-receptor negative breast cancer 10.2 ERBB2 ESR1 PGR
25 gangliosidosis gm1 10.2 ESR1 MTOR PGR
26 poliomyelitis 10.2 ERBB2 ESR1 PGR
27 central nervous system mature teratoma 10.2 ERBB2 ESR1 PGR
28 rectal neoplasm 10.2 ERBB2 ESR1 PGR
29 postpartum depression 10.2 ERBB2 ESR1 PGR
30 male reproductive organ benign neoplasm 10.2 ERBB2 ESR1 PGR
31 central nervous system primitive neuroectodermal neoplasm 10.2 ERBB2 ESR1 PGR
32 polyembryoma of the ovary 10.2 ERBB2 ESR1 PGR
33 intestinal neuroendocrine benign tumor 10.2 ERBB2 PGR
34 arthus reaction 10.2 ERBB2 ESR1 PGR
35 fallopian tube carcinosarcoma 10.2 ERBB2 ESR1 PGR
36 organ system benign neoplasm 10.2 ERBB2 ESR1 PGR
37 ovarian cystadenocarcinoma 10.2 EGFR ERBB2
38 vulva basal cell carcinoma 10.2 ESR1 PGR
39 spinocerebellar ataxia, autosomal recessive 2 10.2 ESR1 MTOR PGR
40 breast duct papilloma 10.2 ERBB2 ESR1 PGR
41 congenital bile acid synthesis defect 10.2 ERBB2 ESR1 PGR
42 metagonimiasis 10.2 ERBB2 ESR1 PGR
43 pituitary stalk meningioma 10.2 ERBB2 ESR1 PGR
44 multinodular goiter 10.2 EGFR ERBB2 MTOR
45 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
46 necrobiosis lipoidica 10.2 ERBB2 ESR1 PGR
47 triple-receptor negative breast cancer 10.2 EGFR ERBB2 PGR
48 skin sarcoma 10.2 EGFR ERBB2 PGR
49 tenosynovitis of foot and ankle 10.2 ERBB2 ESR1 PGR
50 plague 10.2 EGFR ERBB2 ESR1

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:



Diseases related to Luminal Breast Carcinoma

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.13 EGFR MTOR
2 Decreased viability GR00106-A-0 10.13 ERBB3
3 Decreased viability GR00221-A-1 10.13 EGFR ESR1 MTOR
4 Decreased viability GR00221-A-2 10.13 ERBB3 ESR1
5 Decreased viability GR00221-A-3 10.13 ERBB2
6 Decreased viability GR00221-A-4 10.13 EGFR ERBB2 ERBB3 ESR1 MTOR
7 Decreased viability GR00301-A 10.13 ERBB3
8 Decreased viability GR00342-S-1 10.13 MTOR
9 Decreased viability GR00342-S-2 10.13 ERBB3 MTOR
10 Decreased viability GR00342-S-3 10.13 ERBB3
11 Decreased viability with paclitaxel GR00179-A-1 9.7 EGFR MTOR ERBB2
12 Decreased viability with paclitaxel GR00179-A-2 9.7 MTOR
13 Decreased viability with paclitaxel GR00179-A-3 9.7 EGFR MTOR
14 Decreased substrate adherent cell growth GR00193-A-1 9.56 ERBB3
15 Decreased substrate adherent cell growth GR00193-A-2 9.56 EGFR ERBB3 MTOR
16 shRNA abundance <= 50% GR00343-S 9.23 CTR9 EGFR ELF5 ERBB2 ERBB3 ESR1

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.09 CTR9 EGFR ERBB2 ERBB3 ESR1 FOXA1
2 endocrine/exocrine gland MP:0005379 10.06 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
3 cardiovascular system MP:0005385 10.05 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR
4 digestive/alimentary MP:0005381 10.04 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
5 embryo MP:0005380 10.02 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR
6 mortality/aging MP:0010768 10.02 CTR9 EGFR ERBB2 ERBB3 ESR1 FOXA1
7 integument MP:0010771 10.01 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
8 muscle MP:0005369 9.8 ESR1 GATA3 MTOR PGR EGFR ERBB2
9 limbs/digits/tail MP:0005371 9.77 ERBB2 ESR1 KRT5 PGR EGFR
10 neoplasm MP:0002006 9.63 EGFR ERBB2 ERBB3 ESR1 FOXA1 PGR
11 no phenotypic analysis MP:0003012 9.43 EGFR ESR1 GATA3 KRT5 MTOR PGR
12 normal MP:0002873 9.17 ERBB3 EGFR ERBB2 ESR1 GATA3 MTOR

Drugs & Therapeutics for Luminal Breast Carcinoma

Drugs for Luminal Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Estrogens Phase 4,Phase 3,Phase 2,Early Phase 1
2 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
3 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
5 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
6 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
7 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
8 Calcium, Dietary Phase 4
9 vitamin d Phase 4
10
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
11
Phenobarbital Approved Phase 3,Phase 2 50-06-6 4763
12
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
13
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
14
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
15
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
16
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
17
Gemcitabine Approved Phase 3 95058-81-4 60750
18
Letrozole Approved, Investigational Phase 3,Phase 2,Early Phase 1 112809-51-5 3902
19
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
20
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
21
Vinorelbine Approved, Investigational Phase 3,Early Phase 1 71486-22-1 60780 44424639
22
Palbociclib Approved Phase 3,Phase 2 571190-30-2 11431660 5005498 5330286
23
Fluorouracil Approved Phase 3 51-21-8 3385
24
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
25 Anticonvulsants Phase 3,Phase 2
26 Central Nervous System Depressants Phase 3,Phase 2
27 Cytochrome P-450 CYP3A Inducers Phase 3,Phase 2
28 Excitatory Amino Acid Antagonists Phase 3,Phase 2
29 Excitatory Amino Acids Phase 3,Phase 2
30 GABA Agents Phase 3,Phase 2
31 GABA Modulators Phase 3,Phase 2
32 Hypnotics and Sedatives Phase 3,Phase 2
33 Neurotransmitter Agents Phase 3,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Early Phase 1
35 Albumin-Bound Paclitaxel Phase 3,Phase 2
36 Antimitotic Agents Phase 3,Phase 2,Early Phase 1
37 Anti-Infective Agents Phase 3
38 Antimetabolites Phase 3
39 Antimetabolites, Antineoplastic Phase 3
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Antiviral Agents Phase 3
42 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
43 Estrogen Receptor Modulators Phase 3,Phase 2
44 Immunosuppressive Agents Phase 3,Phase 2
45 Selective Estrogen Receptor Modulators Phase 3,Phase 2
46 Protein Kinase Inhibitors Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2
48 Antibiotics, Antitubercular Phase 3,Phase 2
49 Topoisomerase Inhibitors Phase 3,Phase 2
50 Alkylating Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 38)
id Name Status NCT ID Phase
1 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4
2 Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer Recruiting NCT01950182 Phase 3
3 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery Recruiting NCT01864746 Phase 3
4 Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients Active, not recruiting NCT01314833 Phase 3
5 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients Unknown status NCT00432172 Phase 2
6 Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Completed NCT01779479 Phase 2
7 Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer Completed NCT01431196 Phase 2
8 Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer Completed NCT01669252 Phase 2
9 Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone Recruiting NCT02806258 Phase 1, Phase 2
10 Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Recruiting NCT02603679 Phase 2
11 Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy Recruiting NCT03094052 Phase 2
12 A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers Recruiting NCT02238808 Phase 2
13 Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors Recruiting NCT02592083 Phase 2
14 Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Recruiting NCT02213042 Phase 2
15 Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer Recruiting NCT02041338 Phase 2
16 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer Active, not recruiting NCT01565499 Phase 2
17 Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2
18 A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer Active, not recruiting NCT01864798 Phase 2
19 Breast Cancer - Anti-Progestin Prevention Study 1 Not yet recruiting NCT02408770 Phase 2
20 Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Withdrawn NCT02140437 Phase 2
21 A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) Completed NCT00759785 Phase 1
22 Pilot Study of Bisphosphonates for Breast Cancer Recruiting NCT02781805 Phase 1
23 Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients Unknown status NCT01779531
24 Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments Unknown status NCT02284581
25 Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM" Completed NCT02244580
26 Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy Completed NCT02449993
27 Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer Completed NCT01273415
28 Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Completed NCT01377363
29 Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy Completed NCT00911911
30 A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer Recruiting NCT01791829
31 Comparison of the Breast Tumor Microenvironment Recruiting NCT03165487
32 CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages. Recruiting NCT01984866
33 Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) Recruiting NCT02802748 Early Phase 1
34 Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer Recruiting NCT01560663
35 A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) Recruiting NCT02819882
36 Observation of Medical Treatments in MBC HER2-negative Patients Recruiting NCT02365831
37 EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer Not yet recruiting NCT02889874
38 From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers Not yet recruiting NCT02863900

Search NIH Clinical Center for Luminal Breast Carcinoma

Genetic Tests for Luminal Breast Carcinoma

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

39
Breast

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

id Title Authors Year
1
Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. ( 27511992 )
2016
2
p-mTOR expression is associated with better prognosis in luminal breast carcinoma. ( 25053543 )
2014
3
Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas. ( 23754601 )
2013
4
Her2 negative luminal breast carcinoma and Ki-67 evaluation. ( 22647834 )
2012

Variations for Luminal Breast Carcinoma

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 EGFR ERBB2 ERBB3 ESR1 MTOR PGR
2
Show member pathways
12.63 ERBB2 ERBB3 ESR1 MTOR
3
Show member pathways
12.56 EGFR ERBB2 ERBB3 MTOR
4
Show member pathways
12.38 EGFR ERBB2 ERBB3 MTOR
5 12.33 EGFR ERBB2 ERBB3 MTOR
6
Show member pathways
12.32 EGFR ERBB2 ERBB3 MTOR
7
Show member pathways
12.29 ELF5 ERBB2 ESR1 MTOR
8
Show member pathways
12.25 EGFR ERBB2 ERBB3 MTOR
9
Show member pathways
12.1 EGFR ERBB2 ERBB3 ESR1
10
Show member pathways
12.09 EGFR ERBB2 ERBB3
11
Show member pathways
12.05 EGFR ERBB2 ERBB3 MTOR
12 12.02 EGFR ERBB2 MTOR
13 11.99 EGFR ESR1 MTOR
14
Show member pathways
11.95 EGFR ERBB2 MTOR
15 11.93 EGFR ERBB2 ERBB3
16
Show member pathways
11.9 EGFR ERBB2 ERBB3
17
Show member pathways
11.88 EGFR ERBB2 ERBB3 MTOR
18
Show member pathways
11.86 EGFR ERBB2 ERBB3
19 11.75 EGFR ERBB2 MTOR
20
Show member pathways
11.71 EGFR ERBB2 ESR1
21 11.66 EGFR ERBB2 ERBB3 ESR1 MTOR
22 11.51 EGFR ESR1 MTOR
23 11.48 EGFR ERBB2 MTOR
24 11.38 EGFR ERBB2 ERBB3
25 11.23 EGFR ERBB2 ERBB3
26
Show member pathways
11.05 EGFR MTOR
27
Show member pathways
11.05 EGFR ERBB2 ERBB3 ESR1 PGR
28 10.92 EGFR ERBB2 ERBB3
29 10.81 EGFR ERBB2 MTOR

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.85 CTR9 EGFR ELF5 ERBB2 ESR1 FOXA1
2 transcriptionally active chromatin GO:0035327 8.96 CTR9 ESR1
3 receptor complex GO:0043235 8.8 EGFR ERBB2 ERBB3

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.87 ERBB2 ERBB3 GATA3 MTOR
2 transcription from RNA polymerase II promoter GO:0006366 9.85 CTR9 ELF5 ESR1 FOXA1 GATA3
3 negative regulation of gene expression GO:0010629 9.81 ESR1 GATA3 PGR
4 protein autophosphorylation GO:0046777 9.81 EGFR ERBB2 MTOR
5 peptidyl-tyrosine phosphorylation GO:0018108 9.8 EGFR ERBB2 ERBB3
6 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.8 CTR9 EGFR ELF5 ESR1 FOXA1 GATA3
7 positive regulation of protein phosphorylation GO:0001934 9.78 EGFR ERBB2 MTOR
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 EGFR ERBB2 ERBB3
9 phosphatidylinositol phosphorylation GO:0046854 9.72 EGFR ERBB2 ERBB3
10 response to estradiol GO:0032355 9.71 EGFR ESR1 FOXA1
11 chromatin remodeling GO:0006338 9.69 ESR1 FOXA1 GATA3
12 positive regulation of protein kinase B signaling GO:0051897 9.67 EGFR GATA3 MTOR
13 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.65 EGFR ERBB2 ERBB3
14 regulation of ERK1 and ERK2 cascade GO:0070372 9.62 EGFR ERBB2
15 peripheral nervous system development GO:0007422 9.62 ERBB2 ERBB3
16 phosphatidylinositol-mediated signaling GO:0048015 9.62 EGFR ERBB2 ERBB3 MTOR
17 ERBB2 signaling pathway GO:0038128 9.61 EGFR ERBB2 ERBB3
18 anatomical structure formation involved in morphogenesis GO:0048646 9.6 FOXA1 GATA3
19 uterus development GO:0060065 9.59 ESR1 GATA3
20 TOR signaling GO:0031929 9.58 GATA3 MTOR
21 regulation of cell motility GO:2000145 9.58 EGFR ERBB2 ERBB3
22 phosphatidylinositol 3-kinase signaling GO:0014065 9.54 ERBB2 ERBB3 GATA3
23 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.52 ERBB2 MTOR
24 wound healing GO:0042060 9.46 EGFR ERBB2 ERBB3 MTOR
25 regulation of transcription from RNA polymerase II promoter GO:0006357 9.43 EGFR ELF5 ERBB2 ESR1 FOXA1 GATA3
26 negative regulation of ERBB signaling pathway GO:1901185 8.8 EGFR ERBB2 ERBB3
27 regulation of transcription, DNA-templated GO:0006355 10.19 CTR9 ELF5 ERBB2 ESR1 FOXA1 GATA3
28 transcription, DNA-templated GO:0006351 10.16 CTR9 ELF5 ERBB2 ESR1 FOXA1 GATA3
29 signal transduction GO:0007165 10.1 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.91 ELF5 ESR1 FOXA1 GATA3 PGR
2 nucleotide binding GO:0000166 9.76 EGFR ERBB2 ERBB3 MTOR
3 sequence-specific DNA binding GO:0043565 9.72 ELF5 ESR1 FOXA1 GATA3 PGR
4 protein tyrosine kinase activity GO:0004713 9.65 EGFR ERBB2 ERBB3
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 EGFR ERBB2 ERBB3
6 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.58 ELF5 FOXA1 GATA3
7 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.56 ESR1 FOXA1 GATA3 PGR
8 steroid binding GO:0005496 9.49 ESR1 PGR
9 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 EGFR ERBB2
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR ERBB2 ERBB3
11 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR ERBB2 ERBB3

Sources for Luminal Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....